Open AccessThe therapeutic efficacy of Xuanfei Baidu Formula combined with conventional drug in the treatment of coronavirus disease 2019
Author(s) -
Fan Li,
Yajuan Li,
Jingxia Zhang,
Shasha Li,
Ajuan Mao,
Chongbo Zhao,
Weifeng Wang,
Fang Li
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000024129
Subject(s) - medicine , covid-19 , disease , pneumonia , medline , drug , public health , infectious disease (medical specialty) , china , intensive care medicine , medical emergency , pharmacology , pathology , political science , law
Abstract Background: Coronavirus disease 2019 (COVID-19) is a new acute espiratory infectious disease that has been in a public health emergency of international concern. In China, the combination of Xuanfei Baidu Formula (XBF) and conventional drug is used in the clinical treatment of patients with new coronary pneumonia, However, there is no comprehensive and systematic evidence on the effectiveness and safety of XBF. Materials and Methods: We search for research in PubMed, China National Knowledge Infrastructure, Wan-fang Database, China Biomedical Database, and Chinese Science Citation Database. For “Xuanfei Baidu Formula” and “COVID-19,” we screened suitable articles without language restrictions on keywords, Review Manager 5.3 and STATA 14.2 software was used for the data analysis. Results: The systematic review and meta-analysis will evaluate the efficacy and safety of XBF combined with conventional drug in the treatment of COVID-19. Conclusion: We will provide evidence of XBF for the treatment on COVID-19 patients. INPLASY Registration number: INPLASY2020120011